logo-loader

Allergy Therapeutics' £20mln fundraise gets green light from investors

Published: 12:17 30 Mar 2015 BST

test_tubes_350_55194d5a04e19

Shares in the drug developer Allergy Therapeutics (LON:AGY) were higher in morning trade after investors gave the green light to a £20mln share placing that will fund the development of its grass allergy vaccine.

The vote in favour of the fund-raise at today’s general meeting allows the company to issue new stock to investors at 22.1p a share.

It is also an important milestone in the life of lead product Pollinex Quatro Grass, an allergy vaccine tapping into a market estimated to be worth US$2bn a year.

Its clinical development was put on hold by the US Food & Drug Administration in 2007 after a patient taking part in a clinical trial reported numbness and weakness. It took five years to lift the embargo.

Allergy Therapeutics has already carried out clinical studies, including a phase III trial and the FDA has confirmed the data gleaned from them remains valid.

The cash call will fund a number of other investigations, including a further phase III trial efficacy trial.

Successfully negotiating these hurdles would pave the way for the launch of Pollinex Quatro Grass in 2019.

At midday, the stock was up 3% at 19.8p, valuing the business at £80mln.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

1 hour, 39 minutes ago